The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2024 | Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, discusses leukemia stem cell (LSC)-targeting therapies for the treatment of acute myeloid leukemia (AML). Although the specific targeting of LSCs holds promise for improving clinical outcomes, there is limited therapeutic application at this stage, and further investigation is required in order for any clinical benefits to be realized. Immunological approaches and targeting of molecular pathogenesis pathways are currently being explored. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
